The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

2 型糖尿病、胰腺炎和癌症中的外分泌和内分泌胰腺

基本信息

批准号：
10447150
负责人：
Santhi Swaroop Vege
金额：
$ 47.7万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-28 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10447150
关键词：
Abdominal Pain Admission activity Ancillary Study Awareness Biological Biological Markers Biometry Clinic Clinic Activity Clinical Clinical Research Communities Consult Diabetes Mellitus Diagnosis Discipline Disease Early Diagnosis Enrollment Ensure Environment Epidemiology Evaluation Exocrine pancreas Goals Heterogeneity Incidence Infrastructure Institution Internet Islets of Langerhans Knowledge Laboratories Lead Leadership Life Expectancy Link Longitudinal cohort Longitudinal cohort study Malignant Neoplasms Malignant neoplasm of pancreas Measures Medical Modification Morbidity - disease rate Newly Diagnosed Non-Insulin-Dependent Diabetes Mellitus Outpatients Pain Pain management Pancreas Pancreatic Diseases Pancreatitis Participant Patients Protocols documentation Research Research Infrastructure Research Personnel Research Support Role Salivary Sample Size Solid Techniques Training Validation acute pancreatitis base chronic pancreatitis clinical phenotype clinical practice cohort design diagnostic tool epidemiology study experience improved mortality prospective recruit stem working group

项目摘要

PROJECT SUMMARY / ABSTRACT Since the inception of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium, the Mayo Clinic team has been an active participant, including leadership roles, in multiple initiatives. A key priority of the Consortium is the facilitation of mechanism-based research of chronic pancreatitis, pancreatogenic diabetes mellitus, and pancreatic cancer through systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. The goal of the Mayo Clinic team is to contribute meaningfully to the most useful longitudinal cohorts that will increase our understanding of clinical, epidemiological, and biological characterization of patients with these conditions. The primary longitudinal cohort initiatives (outlined in the PAR) to which Mayo Clinic will continue to contribute are PROCEED and NOD. Mayo Clinic investigators will also extend ancillary studies in PROCEED (salivary biomarkers and internet based pain management techniques for pain in chronic pancreatitis (IMPACT)) that leverage the extensive infrastructure in place. The Consortium has defined three Working Groups (WG) in which Mayo Clinic investigators contribute and provide leadership (chronic pancreatitis (CP), Type 3c diabetes mellitus (T3cDM); pancreatic cancer-DM WG. Our contribution includes solid accrual rates for these studies to date, and successful completion of one ancillary study by the PI, active participation in the design of the NOD cohort and subsequent modifications, and extending accrual for DETECT. Using the existing, highly productive infrastructure we have established, our Specific Aims are to: 1) Continue to prospectively enroll and expand accrual of 100 Mayo patients into the PROCEED cohort. Using the clinical research infrastructure in place, we will also enroll chronic pancreatitis patients and subjects into ancillary studies within the CPDPC that include, among others: salivary biomarkers, MINIMAP, and PAIR. 2) Continue to prospectively enroll and expand accrual of 1,322 newly diagnosed diabetes patients into the NOD study. 3) Continue to lead and extend prospective accrual of 60 Mayo participants into the DETECT study. To accomplish these aims, we will implement and identify new strategies to improve recruitment into the main studies as well as ancillary studies at Mayo Clinic while providing to the CPDPC the scientific, clinical and recruitment experience of our investigators.

项目概要/摘要自慢性胰腺炎、糖尿病和胰腺癌 (CPDPC) 研究启动以来联盟，梅奥诊所团队一直是多个领域的积极参与者，包括领导角色倡议。该联盟的一个关键优先事项是促进慢性病的机制研究通过系统收集的临床数据来诊断胰腺炎、胰源性糖尿病和胰腺癌与生物样本相关的纵向队列研究中的措施。梅奥诊所团队的目标是为最有用的纵向队列做出有意义的贡献，这将增加我们对临床、患有这些疾病的患者的流行病学和生物学特征。主要纵向 Mayo Clinic 将继续参与的队列计划（在 PAR 中概述）是 PROCEED 和点头。梅奥诊所的研究人员还将扩大 PROCEED 的辅助研究（唾液生物标志物和基于互联网的慢性胰腺炎疼痛管理技术（IMPACT））广泛的基础设施到位。该联盟定义了三个工作组 (WG)，其中 Mayo 临床研究人员做出贡献并提供领导（慢性胰腺炎 (CP)、3c 型糖尿病（T3cDM）；胰腺癌-DM WG。我们的贡献包括迄今为止这些研究的可靠应计率， PI 成功完成一项辅助研究，积极参与 NOD 队列的设计以及后续修改，并延长 DETECT 的应计金额。利用现有的、高效的我们建立的基础设施，我们的具体目标是： 1) 继续前瞻性地将 100 名 Mayo 患者纳入 PROCEED 队列并扩大其招募规模。利用现有的临床研究基础设施，我们还将招募慢性胰腺炎患者和受试者参加 CPDPC 内的辅助研究，其中包括：唾液生物标志物、迷你地图和配对。 2) 继续前瞻性招募并扩大 1,322 名新诊断糖尿病患者的纳入范围诺德研究。 3) 继续领导并扩大 60 名 Mayo 参与者的预期招募范围进入 DETECT 研究。为了实现这些目标，我们将实施并确定新的战略，以改善主要部门的招聘工作。梅奥诊所的研究和辅助研究，同时向 CPDPC 提供科学、临床和我们调查员的招聘经验。